search
Back to results

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

Primary Purpose

Chronic Rhinitis, Inflammation of the Nasal Mucosa, Inflammation of Nasal Tissue

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Surgical turbinate reduction procedure
Sponsored by
ArthroCare Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Rhinitis focused on measuring Chronic rhinitis, Nasal Obstruction, Nasal Obstruction Symptoms, Failed Medical Management for Nasal Obstruction, Inflammation of the nasal mucosa, Pediatric Turbinate reduction, Coblation, Arthrocare, ENT, Failed Medical Management for Chronic Sinusitis, Turbinate, Inferior Turbinate Hypertrophy, Bilateral Inferior Turbinate Hypertrophy, Turbinate Hypertrophy, Inferior Turbinate, Bilateral Inferior Turbinate

Eligibility Criteria

6 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patient is >=6 and <=17 years old.
  2. Patient has had symptoms of nasal obstruction for >=6 months.
  3. Patient has nasal obstruction symptoms unresponsive to at least 8 weeks of documented maximum medical management (as described in Section 4.1).
  4. Patient has bilateral hypertrophied inferior turbinates without other abnormalities contributing to nasal obstruction (by nasal evaluation and examination).
  5. Patient and parent /guardian agree to participate in the clinical study and to complete all required visits and evaluations.
  6. Patient (or guardian) must sign IRB approved informed consent form.

Exclusion Criteria:

  1. Patient has clinically significant identifiable structural deformities other than turbinate hypertrophy that may contribute to nasal or upper airway obstruction including:

    1. Septal deviation
    2. Concha bullosa
    3. Enlarged adenoids or tonsils (lingual, palatine, or sphenoid)
    4. Nasal polyps
    5. Nasal valve collapse.
  2. Patient has been diagnosed with obstructive sleep apnea not originating from the turbinates.
  3. Patient has active or chronic upper airway infection that may contribute to nasal obstruction (not including chronic rhinosinusitis).
  4. Patient has active coagulation disorder or patient is receiving anti-coagulants, which cannot be safely stopped for 14 days (7 days prior to surgery and 7 days post-surgery).
  5. Patient has systemic disease affecting the nasal passage(e.g. Wegener's granulomatosis).
  6. Patient is receiving or has received immunotherapy (any type) within 12 months of enrollment.
  7. Patient has a nasal septal perforation.
  8. Patient has had any previous turbinate surgery.
  9. Patient has had any previous nasal surgery.
  10. Patient has had any sinus surgery within 6 months of enrollment.
  11. Patient has had an adenoidectomy within 3 months of enrollment.
  12. Patient is pregnant or potentially pregnant.
  13. Patient or caregiver is incapable of understanding or responding to the study questionnaires.
  14. Patient is participating in another clinical study during the 12 month enrollment period.

Sites / Locations

  • Children's Hospital of San Diego
  • The Children's Hospital
  • Center for Pediatric ENT
  • Advanced ENT & Allergy
  • Pediatric Otolaryngology Nationwide Children's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

I

Arm Description

Surgical turbinate reduction procedure

Outcomes

Primary Outcome Measures

Change in nasal obstruction symptoms at 6-weeks post surgery as measured using a validated health-related quality of life questionnaire (SN5) compared to nasal obstruction symptoms measured before surgery using the same questionnaire.

Secondary Outcome Measures

Morbidity by determining the frequency, type, and severity of any observed adverse events through 12 months following surgical treatment.
To assess durability of treatment using: a. Self-reported obstructive symptoms measures b. Physical examination measures, d. Blinded evaluation of anterior rhinoscopy images

Full Information

First Posted
August 18, 2008
Last Updated
August 25, 2015
Sponsor
ArthroCare Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00737906
Brief Title
Surgical Reduction of the Inferior Turbinates for Nasal Obstruction
Official Title
Surgical Reduction of the Inferior Turbinate Using a Coblation® Device for Treatment of Nasal Obstruction: A Prospective, Multi-center Clinical Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Terminated
Study Start Date
October 2007 (undefined)
Primary Completion Date
October 2012 (Actual)
Study Completion Date
October 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ArthroCare Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary goal of this post-marketing surveillance study is to assess whether surgical turbinate reduction performed using a Coblation® device is associated with reduced nasal obstruction symptoms.
Detailed Description
Chronic rhinitis, or inflammation of the nasal mucosa, is one of the most common causes of nasal obstruction in the pediatric population. Chronic rhinitis may result in mucous gland hypertrophy, engorgement of the vascular system and deposition of collagen in the nasal mucosa. These changes occur most prominently in the inferior turbinate, causing enlargement and nasal obstruction. In children, inferior turbinate hypertrophy is associated with a greater degree of nasal obstruction relative to adults because of their small nasal anatomy. Cases that do not respond to conservative treatments may be considered for one of many surgical procedures, including turbinate excision, submucosal resection, submucosal cautery, laser treatment, cryosurgery, powered microdebridement, or radiofrequency-based ablation. Clinical studies have shown that bipolar radiofrequency-based plasma (Coblation®) devices are capable of creating focal submucosal lesions with minimal or no damage to structures adjacent to the treated area. At present, however, this technique has not been formally evaluated in children. This study will investigate whether surgical turbinate reduction performed using a Coblation device is associated with reduced nasal obstruction symptoms that has failed to improve with other treatment methodologies.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Rhinitis, Inflammation of the Nasal Mucosa, Inflammation of Nasal Tissue
Keywords
Chronic rhinitis, Nasal Obstruction, Nasal Obstruction Symptoms, Failed Medical Management for Nasal Obstruction, Inflammation of the nasal mucosa, Pediatric Turbinate reduction, Coblation, Arthrocare, ENT, Failed Medical Management for Chronic Sinusitis, Turbinate, Inferior Turbinate Hypertrophy, Bilateral Inferior Turbinate Hypertrophy, Turbinate Hypertrophy, Inferior Turbinate, Bilateral Inferior Turbinate

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
Outcomes Assessor
Allocation
N/A
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
I
Arm Type
Experimental
Arm Description
Surgical turbinate reduction procedure
Intervention Type
Procedure
Intervention Name(s)
Surgical turbinate reduction procedure
Intervention Description
Surgical turbinate reduction using the COBLATION device
Primary Outcome Measure Information:
Title
Change in nasal obstruction symptoms at 6-weeks post surgery as measured using a validated health-related quality of life questionnaire (SN5) compared to nasal obstruction symptoms measured before surgery using the same questionnaire.
Time Frame
6 weeks, 6 months, 12 months
Secondary Outcome Measure Information:
Title
Morbidity by determining the frequency, type, and severity of any observed adverse events through 12 months following surgical treatment.
Time Frame
Through 12 months
Title
To assess durability of treatment using: a. Self-reported obstructive symptoms measures b. Physical examination measures, d. Blinded evaluation of anterior rhinoscopy images
Time Frame
6 weeks, 6 months, 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient is >=6 and <=17 years old. Patient has had symptoms of nasal obstruction for >=6 months. Patient has nasal obstruction symptoms unresponsive to at least 8 weeks of documented maximum medical management (as described in Section 4.1). Patient has bilateral hypertrophied inferior turbinates without other abnormalities contributing to nasal obstruction (by nasal evaluation and examination). Patient and parent /guardian agree to participate in the clinical study and to complete all required visits and evaluations. Patient (or guardian) must sign IRB approved informed consent form. Exclusion Criteria: Patient has clinically significant identifiable structural deformities other than turbinate hypertrophy that may contribute to nasal or upper airway obstruction including: Septal deviation Concha bullosa Enlarged adenoids or tonsils (lingual, palatine, or sphenoid) Nasal polyps Nasal valve collapse. Patient has been diagnosed with obstructive sleep apnea not originating from the turbinates. Patient has active or chronic upper airway infection that may contribute to nasal obstruction (not including chronic rhinosinusitis). Patient has active coagulation disorder or patient is receiving anti-coagulants, which cannot be safely stopped for 14 days (7 days prior to surgery and 7 days post-surgery). Patient has systemic disease affecting the nasal passage(e.g. Wegener's granulomatosis). Patient is receiving or has received immunotherapy (any type) within 12 months of enrollment. Patient has a nasal septal perforation. Patient has had any previous turbinate surgery. Patient has had any previous nasal surgery. Patient has had any sinus surgery within 6 months of enrollment. Patient has had an adenoidectomy within 3 months of enrollment. Patient is pregnant or potentially pregnant. Patient or caregiver is incapable of understanding or responding to the study questionnaires. Patient is participating in another clinical study during the 12 month enrollment period.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anthony M Magit, MD
Organizational Affiliation
Children's Associated Medical Group, San Diego, CA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Children's Hospital of San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92123
Country
United States
Facility Name
The Children's Hospital
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Facility Name
Center for Pediatric ENT
City
Boynton Beach
State/Province
Florida
ZIP/Postal Code
33437
Country
United States
Facility Name
Advanced ENT & Allergy
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Facility Name
Pediatric Otolaryngology Nationwide Children's Hospital
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43205
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
11190749
Citation
Hol MK, Huizing EH. Treatment of inferior turbinate pathology: a review and critical evaluation of the different techniques. Rhinology. 2000 Dec;38(4):157-66.
Results Reference
background
PubMed Identifier
14712123
Citation
Chang CW, Ries WR. Surgical treatment of the inferior turbinate: new techniques. Curr Opin Otolaryngol Head Neck Surg. 2004 Feb;12(1):53-7. doi: 10.1097/00020840-200402000-00015.
Results Reference
background

Learn more about this trial

Surgical Reduction of the Inferior Turbinates for Nasal Obstruction

We'll reach out to this number within 24 hrs